Hypertension, Pregnancy-Induced Clinical Trial
Official title:
Comprehensive Postpartum Management for Women With Hypertensive Disorders of Pregnancy: A Randomized Controlled
Investigators propose a comprehensive management program for postpartum patients with HDP who are at risk for severe maternal morbidity and mortality. Our program will emphasize three key components: 1) self-monitoring of blood pressures with app-based reporting connected to our electronic health record, 2) blood pressure management directed by a program navigator with guideline and physician support and 3) facilitated transitions of care to primary care clinicians for hypertension management. Investigators will randomize 300 patents with HDP on postpartum day one with follow up through 3 months postpartum. Primary outcome will be blood pressure reporting at 7-10 postpartum. Secondary outcomes include blood pressure control at 7-10 days postpartum, identification and treatment of severe blood pressures, severe maternal morbidity, hospital readmission, triage visits for hypertension, postpartum and primary care visit attendance, and multiple patient-reported outcome measures. All outcomes will be stratified by race (Black and non-Black) to evaluate disparities and by tight versus usual blood pressure control to evaluate the impact of strict postpartum blood pressure control on outcomes. Investigators hypothesize that a comprehensive postpartum HDP management program will improve hypertension control for all patients and reduce disparities that affect Black patients, and that stricter blood pressure control will be associated with fewer adverse outcomes.
Status | Recruiting |
Enrollment | 300 |
Est. completion date | April 1, 2028 |
Est. primary completion date | April 1, 2026 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria 1. Age >18 years 2. Diagnosed with a Hypertensive Disorder of Pregnancy (HDP), which includes chronic hypertension, preeclampsia, gestational hypertension, HELLP Syndrome (Hemolysis, Elevated Liver enzymes, Low Platelets), or eclampsia (O10, O11, O13, O14, O15, O16) Exclusion Criteria 1. Not able or willing to receive electronic surveys 2. Deemed inappropriate for study enrollment by the bedside nurse 3. Non-English speaking 4. Contraindication to ACOG-recommended hypertension control (i.e. chronic kidney disease, stroke) |
Country | Name | City | State |
---|---|---|---|
United States | Vanderbilt University Medical Center | Nashville | Tennessee |
Lead Sponsor | Collaborator |
---|---|
Vanderbilt University Medical Center | Alex Phelps, MD, Etoi Garrison, MD, PhD, Julia Phillippi, PhD, CNM, Kathryn Lindley, MD, Sarah Osmundson, MD, MS, Soha Patel, MD, MSPH |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Satisfaction with postpartum care | Scale of 1-10 | 6 weeks post delivery | |
Other | Satisfaction with blood pressure care | Scale of 1-10 | 6 weeks post delivery | |
Other | Proportion of patients who respond 'yes' to feeling that their voice is heard | Feeling that their voice is heard | 2 weeks post delivery | |
Other | Perceived Stress (NIH Toolbox) | mean T-score (Range 1-100) | 2 weeks post delivery | |
Other | Self-Efficacy (PROMIS measure) | mean T-score (Range 1-100) | 2 weeks post delivery | |
Other | Edinburgh Postpartum Depression Scale | Mean score (range 1-30) | 2 weeks post delivery | |
Other | Mothers on Respect Index Score | mean score (range 14-84) | 6 weeks post delivery | |
Primary | Proportion of participants with recorded blood pressure values in office | Proportion of participants with blood pressure values recorded in the office | 7-10 days post delivery | |
Secondary | Proportion of participants with recorded blood pressure values, any reporting | Proportion of participants with blood pressure values recorded through any means | 7-10 days post delivery | |
Secondary | Mean systolic blood pressure, 7-10 days | Mean systolic blood pressure | 7-10 days post delivery | |
Secondary | Mean diastolic blood pressure, 7-10 days | Mean diastolic blood pressure | 7-10 days post delivery | |
Secondary | Mean systolic blood pressure, 4-6 weeks post delivery | Mean systolic blood pressure | 4-6 weeks post delivery | |
Secondary | Mean diastolic blood pressure, 4-6 weeks post delivery | Mean diastolic blood pressure | 4-6 weeks post delivery | |
Secondary | Proportion of patients who initiated or increased medications | Initiated or increased medications | 6 weeks post delivery | |
Secondary | Number of contacts with the health care team | Number of contacts with the health care team | 6 weeks post delivery | |
Secondary | Proportion of patients with sustained severe hypertension | Two blood pressures >=160/100 at least 15 minutes apart | 6 weeks post delivery | |
Secondary | Proportion of patients with obstetric triage or emergency department visit | Obstetric triage or emergency department visit | 6 weeks post delivery | |
Secondary | Proportion of patients with hospital readmission for hypertension | Hospital readmission for hypertension | 6 weeks post delivery | |
Secondary | Proportion of patients with postpartum visit attendance | Postpartum visit attendance | 3-6 weeks post delivery | |
Secondary | Proportion of patients with primary care visit attendance | Primary care visit attendance | 3 months post delivery |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03613714 -
Innovation in Postpartum Care for Women With Hypertensive Disorders of Pregnancy
|
N/A | |
Completed |
NCT02338687 -
Low Dose Calcium to Prevent Preeclampsia
|
Phase 4 | |
Completed |
NCT04752475 -
Lasix for the Prevention of De Novo Postpartum Hypertension
|
Phase 3 | |
Completed |
NCT03334149 -
Blood Pressure Monitoring in High Risk Pregnancy to Improve the Detection and Monitoring of Hypertension
|
N/A | |
Recruiting |
NCT03298802 -
Postpartum Management of Hypertension in Pregnancy With Hydrochlorothiazide
|
Phase 3 | |
Completed |
NCT03076619 -
A Clinical Study of Fundus Findings in Toxaemia of Pregnancy
|
N/A | |
Recruiting |
NCT05473767 -
Expanding the Family Check-Up in Early Childhood to Promote Cardiovascular Health of Mothers and Young Children
|
N/A | |
Completed |
NCT03356106 -
Screening and Treatment of Obstructive Sleep Apnea in High-risk Pregnancy
|
N/A | |
Recruiting |
NCT03200743 -
Catestatin and Hypertension in Pregnancy
|
N/A | |
Terminated |
NCT04343235 -
Postpartum Management of Gestational Hypertensive Disorders Using Furosemide
|
Phase 4 | |
Completed |
NCT01508208 -
Comparison of Urine Protein/Creatinine Ratio With 24-hour Urine Protein Excretion in Woman With Hypertensive Disorders
|
N/A | |
Active, not recruiting |
NCT04580927 -
Breastfeeding and Postpartum Cardiovascular Health
|
N/A | |
Recruiting |
NCT03858595 -
Optimizing Gestational Weight Gain, Birth Weight and Other Perinatal Outcomes Among Pregnant Women at Risk of Hypertension in Pregnancy
|
N/A | |
Recruiting |
NCT05655936 -
Eliminating Severe Maternal Morbidity With Heart Health Doulas Trial
|
N/A | |
Completed |
NCT02523781 -
Evaluation of an Information Pamphlet for Postpartum Women That Had a Hypertensive Pregnancy
|
N/A | |
Completed |
NCT01736826 -
Free DNA and Nucleosome Concentrations in Pathological Pregnancies
|
||
Completed |
NCT03556761 -
Furosemide for Accelerated Recovery of Blood Pressure Postpartum
|
Phase 2 | |
Completed |
NCT00949260 -
Hemodynamic Assessment of Healthy and Hypertensive Pregnant Women by Non-Invasive Bio-Reactance
|
N/A | |
Active, not recruiting |
NCT04012151 -
Arm and Finger Measurement for Blood Pressure Surveillance
|
||
Completed |
NCT04615624 -
Furosemide vs. Placebo for Severe Antepartum Hypertension
|
Phase 3 |